News from NORD

It’s Not Too Late to Register for the NORD Summit


 

Food and Drug Administration (FDA) Commissioner Robert Califf, MD, will deliver a keynote address on the opening morning of the NORD Rare Diseases and Orphan Products Breakthrough Summit to take place Oct. 17 and 18 in Arlington Virginia. Approximately one-third of the novel new drugs approved by FDA in recent years have been “orphan” drugs for rare diseases.

Dr. Califf will be joined on the program agenda by more than 25 additional FDA speakers, including Janet Woodcock, MD, Director of FDA’s Center for Drug Evaluation and Research, and Peter Marks, MD, PhD, Director of FDA’s Center for Biologics Evaluation and Research.

On Day Two of the conference, Kate Rawson, Senior Editor at Prevision Policy, will provide the morning keynote with a look ahead at possible implications of the national election for the rare disease community. The NORD Summit attracts medical professionals, patient advocates, and others to examine issues related to rare disease research, diagnosis, treatment, and patient access to care. The conference is open to all. Click here to view the agenda.

Recommended Reading

Can Coenzyme Q10 Supplementation Benefit Patients With MSA?
MDedge Neurology
NORD Announces 2016 Grant Opportunities
MDedge Neurology
Register Now for the NORD Summit!
MDedge Neurology
Running for Rare Team Raises Funds for NORD Program for Undiagnosed Patients
MDedge Neurology
Neuroendocrine Tumor Research Foundation Posts RFPs for $1.2 Million in Grants
MDedge Neurology
Research Training Fellowship in Ataxia is Available
MDedge Neurology
University of Pennsylvania Orphan Disease Center Posts RFPs
MDedge Neurology
Guillain-Barré incidence rose with Zika across Americas
MDedge Neurology
Case-control study points to Zika virus as cause of microcephaly
MDedge Neurology
FDA approves Duchenne muscular dystrophy treatment under ‘accelerated pathway’
MDedge Neurology